Effectiveness and impact of counseling enhanced with electronic cigarettes for harmreduction in smokers with opioid use disorder
Project Number5R01DA055675-03
Contact PI/Project LeaderEL-SHAHAWY, OMAR
Awardee OrganizationNEW YORK UNIVERSITY SCHOOL OF MEDICINE
Description
Abstract Text
ABSTRACT
Combustible cigarettes (CC) use among persons with opioid use disorders (OUD), including those in OUD
methadone and buprenorphine treatment programs (OUDTP), is nearly universal (75~95%). Contributing to
premature mortality and poor quality of life, CC may also promote relapse to opioids. CC smokers in OUDTP
particularly suffer from severe intolerance to nicotine withdrawal discomfort. Even with potent, evidence-based
nicotine replacement therapy (NRT) and extended care interventions, no study has found even modest rates of
sustained CC abstinence among CC smokers in OUDTP. Electronic cigarettes (EC) may be superior to traditional
NRT approaches for tobacco harmreduction either by successful switching to EC completely, or by substantially
reducing the number of cigarettes smoked per day (CPD).
The goal of this R01 application is to test the effectiveness of an 8-week telehealth counseling EC harmreduction
intervention on CPD reduction among adult (≥ 21 years) CC smokers in OUDTP. We propose conducting a
randomized controlled trial (RCT; N=302) to compare telehealth counseling + nicotine EC (Intervention) vs.
telehealth counseling + combination NRT (Control) on CPD reduction. Our intervention approach is guided by the
Information-Motivation-Behavioral Skills model. We will recruit our sample from OUDTP in New York City using
electronic health records, in addition to participant and provider-initiated approaches. The primary outcome at
end-of-intervention (8 weeks) is the proportion of CC smokers achieving 100% CPD reduction [i.e. switching
completely to EC (Intervention Arm) or achieving CC abstinence (Control Arm)], verified by exhaled carbon
monoxide. Secondary outcomes include 100% CPD reduction at 26- and 52-weeks, percent change in CPD
relative to baseline, improvement in markers associated with health outcomes (respiratory symptoms, and
health-related quality of life), and reduction in smoking toxicant exposure as measured by NNAL (a tobacco-
specific carcinogen metabolite) in urine. The specific aims are to: 1) Compare the effect of EC versus NRT on
CPD reduction outcomes, 2) Estimate and compare the effect of EC versus NRT on health outcomes and
CC smoking exposure, 3) Evaluate moderating and mediating factors of the intervention effectiveness.
In Year 1, we will finalize the intervention protocols, surveys, hire and train staff, and create the study database
for proactive recruitment. Recruitment of participants will begin in Year 2 and will roll out over 24 months.
There is a vital need for high‐quality RCTs evaluating EC as a tobacco harmreduction strategy. If effective, EC
would provide an additional tool for tobacco harmreduction among CC smokers in OUDTP. This research has
implications for OUD treatment, as well as tobacco use treatment policy and EC regulations.
Public Health Relevance Statement
PROJECT NARRATIVE
Persons with opioid use disorder in methadone and buprenorphine treatment programs are a very vulnerable
population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving
meaningful clinical outcomes in tobacco treatment. We propose an open-label, randomized controlled trial to
compare the effect of electronic cigarettes to combination nicotine replacement therapy on combustible
cigarettes smoking reduction. If effective, electronic cigarettes would provide an additional tool for tobacco
harm reduction among this difficult-to-treat vulnerable population.
NIH Spending Category
No NIH Spending Category available.
Project Terms
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanolAbstinenceAddressAdherenceAdultBehaviorBehavioralCarbon MonoxideCaringCigarette SmokerClinicalCounselingDatabasesDependenceEcological momentary assessmentEffectivenessEffectiveness of InterventionsElectronic Health RecordElectronic cigaretteExhalationGoalsHarm ReductionHealthInterventionLong-Term CareMeasuresMediatingModelingMotivationNational Institute of Drug AbuseNew York CityNicotineNicotine WithdrawalOpioidOutcomeParticipantPatient RecruitmentsPatient Self-ReportPatternPerceptionPersonsPharmaceutical PreparationsPoliciesPremature MortalityProtocols documentationProviderQuality of lifeRandomized, Controlled TrialsRegulationRelapseResearchRespiratory Signs and SymptomsRitual compulsionSamplingSelf EfficacySmokerSmokingSurveysTarget PopulationsTimeTobaccoTobacco useTobacco-Associated CarcinogenToxicant exposureTrainingUrineVariantVulnerable Populationsarmbuprenorphine treatmentcigarette smokecigarette smokingcombustible cigaretteeffectiveness testingelectronic cigarette useevidence baseexperiencefollow-uphealth related quality of lifeimprovedinterestmeetingsmethadone treatmentnicotine replacementnovelopen labelopioid use disorderpreferenceprimary outcomepulmonary functionrecruitsecondary outcomeskillssmoking cessationsmoking exposuresuccesstelehealthtooltreatment armtreatment program
No Sub Projects information available for 5R01DA055675-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DA055675-03
Patents
No Patents information available for 5R01DA055675-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DA055675-03
Clinical Studies
No Clinical Studies information available for 5R01DA055675-03
News and More
Related News Releases
No news release information available for 5R01DA055675-03
History
No Historical information available for 5R01DA055675-03
Similar Projects
No Similar Projects information available for 5R01DA055675-03